Facebook Linkedin Twitter
Inside Precision Medicine Merck Inks $1B Synthetic Biology Deal with Pearl

Ambrx Biopharma

DNA Molecular Structure
News & Features

Merck Inks $1B Synthetic Biology Deal with Pearl

0
Antibody drug conjugated with cytotoxic payload. Synthetic Biology
News & Features

Johnson & Johnson to Acquire Clinical-Stage Antibody Drug Conjugate Company Ambrx for $2 Billion

0

Related Content

Sage Publishing

Copyright © 2025 Genetic Engineering & Biotechnology News. All Rights Reserved.
Terms of ServicePrivacy Policy

Sage Publishing
Inside Precision Medicine